

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)



(10) International Publication Number
WO 2023/111147 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) *A61K 9/00* (2006.01)
A61K 47/69 (2017.01) *A61K 47/26* (2006.01)
A61K 31/7068 (2006.01) *A61P 35/00* (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/EP2022/086083

(22) International Filing Date:

15 December 2022 (15.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2118225.8 16 December 2021 (16.12.2021) GB

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **PHION THERAPEUTICS LTD** [GB/GB]; 63 University Road, Research And Enterprise, Belfast BT7 INF (GB).

(72) Inventors: **MCCARTHY, Helen**; Phion Therapeutics Ltd, 63 University Road, Research And Enterprise, Belfast BT7 INF (GB). **BENNIE, Lindsey Ann**; Phion Therapeutics Ltd, 63 University Road, Research And Enterprise, Belfast BT7 INF (GB). **CHAMBERS, Philip**; Phion Therapeutics Ltd, 63 University Road, Research And Enterprise, Belfast BT7 INF (GB).

(74) Agent: **PADGET, Lucy**; Alembia Intellectual Property Ltd, Biohub at Alderley Park, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NUCLEOSIDE FORMULATION

(57) Abstract: The present specification relates to a nucleoside formulation which comprises a nucleoside or a phosphate thereof; and an amphipathic cell penetrating RALA peptide. In one embodiment, the nucleoside formulation comprises gemcitabine or a phosphate thereof and the peptide WEARLARALARALARHLARALARALRACEA.

WO 2023/111147 A1